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Key Summary Points
Truncal acne has historically been
overlooked in clinical evaluations and
trials, resulting in a lack of evidence-based
treatment options
Despite the lack of randomized clinical
trials and treatment guidelines involving
the trunk, we have typically relied on
benzoyl peroxide washes, oral antibiotics,
and isotretinoin for truncal acne
treatment
Some progress has been made in recent
years with certain trials including truncal
acne evaluation, for example lidoseisotretinoin, sarecycline, dapsone, and
trifarotene
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Trifarotene is the first topical retinoid with
robust evidence from large-scale,
randomized, vehicle-controlled phase III
studies, supporting its use as a first-line
acne treatment for both the face and
trunk
It is time we consider evidence-based
treatments for our patients with
combined facial and truncal acne, to help
improve outcomes and relieve the burden
on their lives
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DIGITAL FEATURES
This article is published with digital features,
including a summary slide, to facilitate understanding of the article. To view digital features
for this article go to https://doi.org/10.6084/
m9.figshare.14356220.

COMMENTARY
Truncal acne (back and/or chest) is a common
presentation of acne vulgaris, affecting approximately 50% of people with facial acne [1].
However, truncal acne has historically been
overlooked in both clinical evaluations during
consultations and clinical trials, resulting in a
lack of evidence-based treatment options.
Indeed, the treatment landscape has remained
largely the same for many decades. We have
typically relied on benzoyl peroxide (BPO)
washes, oral antibiotics, and isotretinoin for
truncal acne treatment, despite the lack of randomized clinical trials and treatment guidelines
involving the trunk [1]. In the hope of providing better outcomes for our patients, we must
avoid inferring efficacy and tolerability on the
trunk from facial acne data and look towards
gaining robust evidence. Here, we will explore
different treatments available for the trunk,
including sarecycline and trifarotene, and discuss important considerations for the treatment
of truncal acne.
Current treatment guidelines for acne management have limited guidance for the trunk,
and thus we continue to manage acne on the
back, shoulders, and chest, on the basis of
guidelines specifically for facial acne [1]. In our
experience, many dermatologists consider systemic therapy a necessary part of the treatment
regimen owing to the involvement of large
body surface areas in truncal acne. Moreover,
there can be some reluctance to use topical
agents as a first-line treatment for truncal acne
due to the perception of limited efficacy and
potential for irritation with retinoids on the
trunk, and bleaching effects of BPO on clothing
and bed linen.

Systemic therapy like oral isotretinoin, particularly the lidose formulation with some evidence on the trunk, is a valid option for severe
inflammatory and nodular acne for those willing to use it [2]. However, a combination regimen involving fixed combinations of topical
agents (e.g., retinoid/BPO or clindamycin/BPO)
or topical therapies plus systemic antibiotics is
generally recommended for other cases [1]. In
fact, for patients who present with mild or
moderate truncal acne, topical monotherapy
may be adequate as both initial and maintenance treatment [1]. Topical treatment on
extensive and hard-to-reach areas such as the
back and shoulders can be challenging for
patients; thus, wash-off formulations of BPO are
often recommended for convenient application
in the shower and to minimize bleaching/discoloration of clothing and bedsheets [3]. However, the limited clinical studies available
demonstrate that the very brief exposure of the
skin to wash-off formulations can result in
suboptimal antimicrobial efficacy (Cutibacterium acnes reduction), exemplifying the need
for alternative topical formulations and treatments such as short contact, ‘‘leave-on’’ emollient foams, gels, or creams [3].
Historically, truncal acne has been studied
less than facial acne but there has been some
progress in recent years, with trials that have
evaluated different systemic and topical therapies on the trunk—some with more robust evidence than others. Sarecycline (1.5 mg/kg/day)
is a once-daily, narrow-spectrum tetracycline
for the treatment of moderate to severe acne,
which was recently evaluated in two identically
designed, randomized, placebo-controlled,
12-week, phase III studies in the USA. The primary endpoint for these trials was Investigator
Global Assessment (IGA) and inflammatory and
non-inflammatory lesion count reduction on
the face. Although these studies were not statistically powered to evaluate the effect of sarecycline on the trunk, the back and chest were
also evaluated using IGA scores, providing some
beneficial evidence for the treatment of moderate to severe truncal acne [4]. In terms of
topical treatments, dapsone 7.5% gel is an antiinflammatory agent that is commonly used for
the treatment of truncal acne in the USA. It has
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been evaluated in one small (n = 20), open-label, pilot study, which demonstrated efficacy in
patients with moderate truncal acne over
16 weeks [5].
Perhaps the most robust evidence for truncal
acne comes from trifarotene (50 lg/g cream),
the first new retinoid molecule for the treatment of acne in 25 years, approved by the US
Food and Drug Administration (FDA) and
European Medicines Agency (EMA) [6, 7]. Trifarotene is a potent, topical retinoid that selectively targets retinoic acid receptor-c. This
targeted activity results in low systemic exposure, making it suitable for application on the
face and large body surface areas like the trunk.
Moreover, we consider the vehicle for trifarotene cream to be easily spreadable, with a
suitable texture for truncal application. The
trifarotene pivotal studies are the first largescale, randomized, vehicle-controlled trials of a
topical acne treatment to evaluate the trunk as
an official endpoint using the Physician Global
Assessment (PGA) scale (N = 2420 patients) [6].
Trifarotene treatment significantly reduced
both comedones and inflammatory lesions on
the face and trunk over 12 weeks versus vehicle
(p \ 0.001), demonstrating that topical retinoids can be suitable for first-line treatment of
truncal acne [6]. Given some dermatologists’
perception that retinoids may be unsuitable for
the trunk, it is encouraging to see that trifarotene was well tolerated on both the trunk
and face, and that the tolerability and safety
profile was acceptable and manageable overall
[6]. From our practical clinical experience, it
seems that trifarotene may be a good option
even for those with dry skin or prone to atopic
dermatitis.
Acne is a long-term disease, so we must
evaluate long-term safety data for any treatment. Unlike most long-term safety trials that
include patients from the main phase III efficacy trials, the long-term safety of trifarotene
was independently evaluated in a multicenter,
open-label study of 453 patients [7]. Therefore,
it is very likely that the manageable tolerability
and safety profile, and high treatment compliance rates (greater than 95% on the face and
trunk) observed over 1 year are representative of

a ‘‘true’’ acne patient population and relevant to
clinical practice [7].
The trifarotene pivotal studies demonstrated
its efficacy as a monotherapy; in clinical practice, trifarotene could be prescribed alone or in
combination with BPO or oral antibiotics, with
no contraindications for combining these
treatments. Currently, trifarotene is being evaluated in combination with oral doxycycline in a
phase IV trial including patients with severe
acne, with results expected in 2021
(NCT04451330). However, the selection of
combination regimens should depend on acne
severity, patient history, suitability, and,
importantly, preference. In our experience,
many dermatologists avoid prescribing isotretinoin because of the legal implications and
responsibility such as the need for written,
informed consent and repeated pregnancy
testing every 4 weeks. Similarly, a growing
number of patients do not wish to use oral isotretinoin because of the pregnancy contraindication and numerous follow-up tests needed for
monitoring side effects. Many dermatologists
are also reluctant to prescribe oral antibiotics
because of the increasing risk of bacterial resistance and because treatment adherence can be
low. Therefore, trifarotene represents an
important, new treatment option for the trunk,
which may reduce superfluous use of antibiotics
in acne treatment.
Regardless of the combination regimen that
is selected, we must provide adequate guidance
to our patients for topical application, including the use of mild or soapless cleansers and
moisturizer to minimize skin dryness and irritation. Patients are typically educated/influenced by the media to ‘‘spot’’ treat; however,
field treatment is more appropriate for large
surface areas of the trunk.
Ultimately, we must be willing to encompass
evidence-based alternatives to systemic treatments where possible and seek better topical
application approaches for our patients. We
must also collectively strive to provide equal
importance to both the face and trunk in both
clinical research and consultations to provide
the most suitable treatments. This will help us
prevent the long-term sequelae of acne such as
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scarring and dyspigmentation and relieve the
burden of acne on our patients.
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